Stock Detail
ARENA PHARMACEUTICALS INC
Biotechnology
ARNA @ Yahoo Finance | ARNA Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.38 | $1.41 | $-0.02 | -1.43% | 0.00 | $1.40 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.38 | $1.37 | 846,813 | 201.51M | 1.57M | -1.59 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.43 | 1.41 | 1.39 | 1.37 | 1.35 |
Stock Profile
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs in the therapeutic areas of metabolic, cardiovascular, inflammatory, and central nervous system diseases. The company is developing a pipeline of compounds that act on drug targets called G protein-coupled receptors, using its proprietary technologies, including Constitutively Activated Receptor Technology and Melanophore. Arena's products principally include APD356, a Phase II clinical trial 5-HT2C serotonin receptor agonist, which would be used for the treatment of obesity; and APD125, a Phase I clinical trial product, for the treatment of insomnia. Arena Pharmaceuticals has research collaborations with Ortho-McNeil Pharmaceutical, Inc. and Merck & Co., Inc. for products in various indications. The company was co-founded by Dominic P. Behan and Jack Lief. Arena Pharmaceuticals was incorporated in 1997 and is based in San Diego, California.